117 related articles for article (PubMed ID: 14725792)
1. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies.
Wang JN; Feng JN; Yu M; Xu M; Shi M; Zhou T; Yu XD; Shen BF; Guo N
Mol Immunol; 2004 Feb; 40(13):963-9. PubMed ID: 14725792
[TBL] [Abstract][Full Text] [Related]
2. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
3. A novel ErbB2 epitope targeted by human antitumor immunoagents.
Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C
FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302
[TBL] [Abstract][Full Text] [Related]
4. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C
FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
De Lorenzo C; Troise F; Cafaro V; D'Alessio G
Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
[TBL] [Abstract][Full Text] [Related]
6. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
[TBL] [Abstract][Full Text] [Related]
7. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
Neve RM; Nielsen UB; Kirpotin DB; Poul MA; Marks JD; Benz CC
Biochem Biophys Res Commun; 2001 Jan; 280(1):274-9. PubMed ID: 11162510
[TBL] [Abstract][Full Text] [Related]
8. Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.
Chang L; Zhou C; Xu M; Liu J
J Comput Aided Mol Des; 2010 Jan; 24(1):37-47. PubMed ID: 20012671
[TBL] [Abstract][Full Text] [Related]
9. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.
Price-Schiavi SA; Jepson S; Li P; Arango M; Rudland PS; Yee L; Carraway KL
Int J Cancer; 2002 Jun; 99(6):783-91. PubMed ID: 12115478
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
11. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
[TBL] [Abstract][Full Text] [Related]
12. Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis.
Franco-Gonzalez JF; Cruz VL; Ramos J; Martínez-Salazar J
J Mol Model; 2013 Mar; 19(3):1227-36. PubMed ID: 23160933
[TBL] [Abstract][Full Text] [Related]
13. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
17. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.
Gelardi T; Damiano V; Rosa R; Bianco R; Cozzolino R; Tortora G; Laccetti P; D'Alessio G; De Lorenzo C
Br J Cancer; 2010 Feb; 102(3):513-9. PubMed ID: 20051960
[TBL] [Abstract][Full Text] [Related]
18. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
20. Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor.
Wels W; Harwerth IM; Hynes NE; Groner B
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):1-7. PubMed ID: 1381944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
